Table of Contents
Advances in Biomaterials
Volume 2014, Article ID 261281, 8 pages
http://dx.doi.org/10.1155/2014/261281
Research Article

Plasma-Mediated Immobilization of Antibody with PEG as Spacer for Enhanced Endothelial Cell Adhesion and Proliferation

Yuan Yuan,1,2,3 Jing Zhang,1,2,3 Min Yin,2,3 and Changsheng Liu1,2,3

1The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China
2Key Laboratory for Ultrafine Materials of Ministry of Education and Engineering, East China University of Science and Technology, Shanghai 200237, China
3Research Center for Biomedical Materials of Ministry of Education, East China University of Science and Technology, Shanghai 200237, China

Received 27 December 2013; Accepted 16 February 2014; Published 10 April 2014

Academic Editor: Traian V. Chirila

Copyright © 2014 Yuan Yuan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Immobilization of anti-CD34 antibody is proven to be an effective strategy to accelerate reendothelialization and thereby lower the thrombosis of blood contacting grafts. To realize highly efficient immobilization of anti-CD34 antibody, an argon cold plasma-mediated graft process was developed with PEG as spacer arm in this study. In this process, the 316L stainless steel (316LSS) model substrate was first coated with ethylene vinyl acetate copolymer (EVA) followed by argon plasma treatment and PEG400 modification (EVA-PEG). The EVA-PEG was further ignited by argon plasma and then the anti-CD34 antibody was immobilized. XPS measurement indicated the successful immobilization of the EVA and the anti-CD34 antibody molecules. Compared with the anti-CD34 antibody anchored without PEG, the immobilized EVA-PEG-anti-CD34 antibody exhibited better capturing efficiency (increase about 1-fold) of specific antigen. Consequently, the endothelial cell attachment (before 12 h) and proliferation (1~4 days) were significantly improved. Further study showed that this EVA-PEG-anti-CD34 coating could reduce blood coagulation. Therefore, this cold plasma-mediated graft process with PEG spacer arm developed here is a promising strategy to immobilize antibody with higher bioactivity for rapid reendothelialization of the cardiovascular implants.